IBC Life Sciences

"This is an opportunity to interact with many of the key players in the field at one event."
- George A. Heavner, Ph.D., Distinguished Research Fellow, Centocor, Inc.

"Given the industry's infancy in developing oligonucleotide therapeutics, the TIDES® conference provides an extremely valuable way to stay up to date and interact with colleagues involved with this fast-moving landscape."
- Daren S. Levin, Ph.D., Investigator, Inhaled Product Development, GlaxoSmithKline

"TIDES® is the premier event for all things RNA/DNA related, to learn what is going on and to meet all the players in the field."
- David Macdonald, Director of Chemical Development, Agilent Technologies

"One of the great meetings for anyone involved or interested in any aspect of our industry."
- Louis St.L. O'Dea, MD, FRCP(C), Senior Vice President and Chief Medical Officer, Radius Health, Inc.

"TIDES® provides an outstanding opportunity to establish and intensify contacts to people in the oligonucleotide business as well as to learn about new developments and trends in the therapeutic oligonucleotide area."
- Hueseyin Ayguen, Ph.D., CSO, Nucleic Acid Technologies, BioSpring GmbH, Germany

"Will provide much-needed insights into the challenges and potential of moving these therapeutics from the bench to the clinic."
- Mark L. Peterson, Ph.D., Vice President, IP & Operations, Tranzyme Pharma Inc., Canada

"TIDES® provides an excellent forum for colleagues from different functional areas to understand the challenges related to the co-development of therapeutics and diagnostics."
- Helen Wu, Ph.D., Research Leader, Genomics and Oncology, Roche Molecular Systems, Inc.

"The TIDES® conference is the place to be to learn new technologies related to the peptide industry and to network with some of the world leaders in the field."
- Nicolas Mourier, Ph.D., Director of Product Development, Peptimmune, Inc.

"TIDES® has always been an excellent forum for education."
- Nadim Akhtar, Ph.D., Senior Scientist, Astra Zeneca, United Kingdom